Abstract

The activation of dioxygen is the keystone of all forms of aerobic life. Many biological functions rely on the redox versatility of metal ions to perform reductive activation-mediated processes entailing dioxygen and its partially reduced species including superoxide, hydrogen peroxide, and hydroxyl radicals, also known as reactive oxygen species (ROS). In biomimetic chemistry, a number of synthetic approaches have sought to design, synthesize and characterize reactive intermediates such as the metal-superoxo, -peroxo, and -oxo species, which are commonly found as key intermediates in the enzymatic catalytic cycle. However, the use of these designed complexes and their corresponding intermediates as potential candidates for cancer therapeutics has scarcely been endeavored. In this context, a series of biomimetic first-row transition metal complexes bearing a picolylamine-based water-soluble ligand, [M(HN3O2)]2+ (M = Mn2+, Fe2+, Co2+, Cu2+; HN3O2 = 2-(2-(bis(pyridin-2-ylmethyl)amino)ethoxy)ethanol) were synthesized and characterized by various spectroscopic methods including X-ray crystallography and their dioxygen and ROS activation reactivity were evaluated in situ and in vitro. It turned out that among these metal complexes, the iron complex, [Fe(HN3O2)(H2O)]2+, was capable of activating dioxygen and hydrogen peroxide and produced the ROS species (e.g., hydroxyl radical). Upon the incubation of these complexes with different cancer cells, such as cervical, breast, and colorectal cancer cells (MDA-MB-231, AU565, SK-BR-3, HeLa S3, HT-29, and HCT116 cells), only the iron complex triggered cellular apoptosis specifically for colorectal cancer cells; the other metal complexes show negligible anti-proliferative activity. More importantly, the biomimetic complexes were harmless to normal cells and produced less ROS therein. The use of immunocytochemistry combined with western blot analysis strongly supported that apoptosis occurred via the intrinsic mitochondrial pathway; in the intracellular network, [Fe(HN3O2)(H2O)]2+ resulted in (i) the activation and/or production of ROS species, (ii) the induction of intracellular impaired redox balance, and (iii) the promotion of the mitochondrial apoptotic signaling pathway in colorectal cancer cells. The results have implications for developing novel biomimetic complexes in cancer treatments and for designing potent candidates with cancer-specific antitumor activity.

Highlights

  • Cancer is one of the most harmful and serious heterogeneous diseases that represent abnormal cellular energy metabolism and remains one of the major causes of death in most developing and developed countries.[1]

  • A series of biomimetic first-row transition metal complexes bearing a picolylamine-based water-soluble ligand, [M(HN3O2)]2+ (M 1⁄4 Mn2+, Fe2+, Co2+, Cu2+; HN3O2 1⁄4 2-(2-(bis(pyridin-2-ylmethyl)amino)ethoxy)ethanol) were synthesized and characterized by various spectroscopic methods including X-ray crystallography and their dioxygen and reactive oxygen species (ROS) activation reactivity were evaluated in situ and in vitro

  • Since a 2-His-1carboxylate facial triad is a common feature of the active sites in dioxygen-activating nonheme metalloenzymes,[43,44,45,46] we rst explored the dioxygen activation reactivity of [M(HN3O2)]2+ under aerobic reaction conditions

Read more

Summary

Introduction

Cancer is one of the most harmful and serious heterogeneous diseases that represent abnormal cellular energy metabolism and remains one of the major causes of death in most developing and developed countries.[1]. Edge Article cancer treatments to date.[2,3,4] Despite the outstanding applicability of Pt-based drugs, they suffer from low stability under physiological conditions resulting in copious toxic side effects such as necrosis, tissue injury, nausea, vomiting, and neurotoxicity.[5,6,7,8] Ever since the pioneering work of the Au(I)–NHC complex was reported by Bernes-Price and co-workers in 2004,9 recent developments in the design of non-Pt-based metal Nheterocyclic carbene (NHC) complexes, such as those of Ru, Au, Ir, and Pd, have succeeded in the signi cant improvement of their stability due to the strong donating ability of the NHC ligand.[10,11,12,13,14,15] Still, these metals are non-existing elements for the human body and may be the source of unexpected side effects along with the development of drug resistance.[16,17,18,19] the use of rst-row transition metals such as Mn, Fe, Co, and Cu would be a credible alternative route for generation anticancer agents with low general toxicity because they are biorelevant trace elements. The anticancer activity of rst-row transition metal-based drugs have mostly been examined by introducing or vectorizing metal chelators as potential chemotherapeutics;[26,27,28,29,30,31] their in situ mechanism of action and reactivity were scarcely scrutinized due to the intrinsic instability of reactive metal–oxygen intermediates

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call